APA

Driessen M. T., Whalen J., Buguth B. S., Vallejo-Aparicio L. A., Naya I. P., Asukai Y., Alcázar-Navarrete B., Miravitlles M., García-Río F. & Risebrough N. A. (012019). Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. : Respiratory research.

Chicago

Driessen M T, Whalen J, Buguth B Seewoodharry, Vallejo-Aparicio L A, Naya I P, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F and Risebrough N A. 012019. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. : Respiratory research.

Harvard

Driessen M. T., Whalen J., Buguth B. S., Vallejo-Aparicio L. A., Naya I. P., Asukai Y., Alcázar-Navarrete B., Miravitlles M., García-Río F. and Risebrough N. A. (012019). Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. : Respiratory research.

MLA

Driessen M T, Whalen J, Buguth B Seewoodharry, Vallejo-Aparicio L A, Naya I P, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F and Risebrough N A. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. : Respiratory research. 012019.